Patent 7470513 Issued on December 30, 2008. Estimated Expiration Date: November 10, 2023. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS/TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test.
Other References
Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, Relling MV, Evans WE. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med. 1997, 126(8):608-14.
Wolkenstein P, Carriere V, Charue D, Bastuji-Garin S, Revuz J, Roujeau JC, Beaune P, Bagot M. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics. 1995, 5(4):255-8.
Svensson CK, Cowen EW , Gaspari, AA. (2000) Cutaneous drug reactions. Pharmacol Rev. 53(3):357-379.
Shirato S, Kagaya F, Suzuki Y, Joukou S. Stevens-Johnson syndrome induced by methazolamide treatment. Arch Ophthalmol. 1997, 115(4):550-3.
Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia-O, Locati F, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995, 333(24):1600-7.
Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994, 331(19):1272-85.
Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol. 1994, 102(6):28S-30S.
Roujeau JC, Bracq C, Huyn NT, Chaussalet E, Raffin C, Duedari N. HLA phenotypes and bullous cutaneous reactions to drugs. Tissue Antigens. 1986, 28(4):251-4.
Pirmohamed M , Lin K, Chadwick D, Park BK. TNFα promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology. 2001, 56(7):890-6.
Pichler WJ, Zanni M, von Greyerz S, Schnyder B, Mauri-Hellweg D, Wendland T. High IL-5 production by human drug-specific T cell clones. Int Arch Allergy Immunol. 1997, 113(1-3):177-80.
Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, Pichler WJ, Pirmohamed M, Park BK. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol. 2003, 63(3):732-41.
Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia. 1998, 39 Suppl 7:S8-16.
Lazarou J, Pomeranz BH, Corey PN, (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 279(15):1200-1205.
Khan MA. Update: the twenty subtypes of HLA-B27. Curr Opin Rheumatol. 2000;12(4):235-8.
Hari Y, Frutig-Schnyder K, Hurni M, Yawalkar N, Zanni MP, Schnyder B, Kappeler A, von Greyerz S, Braathen LR, Pichler WJ. T cell involvement in cutaneous drug eruptions. Clin Exp Allergy. 2001, 31(9):1398-408.
Green VJ, Pirmohamed M, Kitteringham NR, Gaedigk A, Grant DM, Boxer M, Burchell B, Park BK. Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity. Biochem Pharmacol.1995, 50(9):1353-9.
Gennis MA, Vemuri R, Burns EA, Hill JV, Miller MA, Spielberg SP. Familial occurrence of hypersensitivity to phenytoin. Am J Med. 1991, 91(6):631-4.
Feltkamp TE, Mardjuadi A, Huang F, Chou CT. Spondyloarthropathies in eastern Asia. Curr Opin Rheumatol. 2001, 13(4):285-90.
Edwards SG, Hubbard V, Aylett S, Wren D. Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins. Postgrad Med J. 1999, 75(889):680-1.
Chan SH and Tan T. “HLA and allopurinol drug eruption” Dermatologica. 1989, 179(1):32-3.
Bigby M, Jick S, Jick H, Amdt K. (1986) Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 256(24):3358-3363.
Romphruk, A., et al. (2003). HLA-B* 15 subtypes in the population of north-eastern Thailand. Eur J Immunogenet. 30(2):153-158.
Pirmohamed, M., and Park, B.K. (2003). Adverse drug reactions: back to the future. Br J Clin Pharmacol. 55(5):486-492.
Nassif, A., et al. (2002). Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol. 118(4):728-733.
Mallal, S. et al. (2002). Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 359(9308):727-732.
Hildesheim, A., et al. (2002). Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst. 94(23):1780-1789.
Gut, J. (2002). Severe adverse drug reactions and theragenomics. Business Briefing Pharmatech. Retrieved from the Internet: URL: http://therastrat.com/downloads/Gut—2002—Servere—Adverse—Drug—Reactions.pdf> retrieved on Oct. 1, 2004.
Gumperz, J.E., et al. (1995). The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med. 181(3):1133-1144.
Chung, W.H., et al. (2004). Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 428(6982):486.
Hoa BK et al, Tissue Antigens, 2007, 71:127-134.
Saito S et al, Tissue Antigens, 2000, 56:522-529.
Hung S et al ‘Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions’ 2006 Pharmacogenetics and Genomics, vol. 16 No. 4, p. 297-306.
Wu Y et al ‘Activation of T cells by carbamazepine and carbamazepine metabolites’, J Allergy CLin Immunol, Jul. 2006, p. 233-241.
Sankar, P, Nature Genetics (2003), vol. 34, p. 119.
Alfirevic A et al ‘HLA-B locus in Caucasian patients with carbamazepine hypersensitivity.’ Pharmacogenomics. Sep. 2006;7(6):813-8.
Lonjou c et al ‘A marker for Stevens-Johnson syndrome . . . : ethnicity matters’. Pharmacogenomics J. Jan. 17, 2006, pp. 1-4.
Carbamazepine, available online at www.mentalhealth.com/drug/p30-t01.html, pp. 1-17.
Hung et al ‘HLA-B genotyping to detect carbamazepine-induced Stevens-Johnson syndrome: implications for personalizing medicine’. Personalized Medicine, Aug. 2005, vol. 2, No. 3, pp. 225-237.
Deng et al ‘LOD score exclusion analyses for candidate genes using random population samples’. Ann Hum Genet. May 2001;65(Pt 3):313-29.
Thisted RA ‘What is a P-value?’ (1998) available online at http://www.stat.uchicago.edu?˜thisted, pp. 1-6.
Juppner H ‘Functional properties of the PTH/PTHrP receptor’. Bone. Aug. 1995;17(2 Suppl):39S-42S.
November 10, 2023. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
